Skip to content
TrialScanner

NCT03643107

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Phase 2CompletedALLRLeadLTRNCollaborator

Registry record

Lead sponsor
Allarity Therapeutics
Conditions
Metastatic Castration-Resistant Prostate Cancer Patients
Primary completion
Oct 1, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03643107 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03643107: Irofulven in AR-targeted and... | TrialScanner